Table 3Reboxetine – evidence map for relapse prevention trial

RBX vs. plc
Non-therapy-resistant population
RBX vs. plc
Fluoxetine-resistant population
Outcome
Relapse rate at end of study(R+)
Depression scale total score(R+)no data
Mortality(↔)(↔) (no events)
Suicidal tendencies(↔)(↔) (no events)
Suicide attempts & suicides(↔)(↔) (no events)
Total rate of SAE
Total rate of AE
Discontinuations due to AE

R+/R−: superiority/inferiority of reboxetine

(R+)/(R−): indication of superiority/inferiority of reboxetine

↔ : no proof of superiority or inferiority of one of the 2 treatment options

(↔): no proof of superiority or inferiority of one of the 2 treatment options, with insufficient data

AE: adverse events; plc: placebo; RBX: reboxetine; SAE: serious adverse events

© IQWiG (Institute for Quality and Efficiency in Health Care)

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.